Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3757253 | 0.97 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL9733197 | 0.97 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL6081619 | 0.97 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL9093331 | 0.97 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3162750 | 0.87 | LMNA (0.77) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL1467165 | 0.86 | LMNA (0.74) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL4476489 | 0.86 | LMNA (0.74) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL964866 | 0.86 | LMNA (0.74) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL5279915 | 0.86 | LMNA (0.74) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3168002 | 0.84 | LMNA (0.72) | LMNACHRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118048412-B | Preparation method of aspergillus fumigatus tremorine C | 青岛普瑞迈生物工程有限公司 | 2024-12-10 | — | — | CN | claimed |
| US-20240336977-A1 | MICRORNA-REGULATED BIOMARKERS AND DRUG TARGETS FOR IMPROVING DIAGNOSIS AND TREATMENT OF LUNG OR BREAST CANCER | West Virginia University Board of Governors on behalf of West Virginia University (US) | 2024-10-10 | — | — | US | claimed |
| CN-118090975-A | Method for simultaneously measuring multiple mycotoxins in biodegradable food contact material | 南宁海关技术中心 | 2024-05-28 | — | — | CN | claimed |
| CN-118048412-A | Preparation method of aspergillus fumigatus tremorine C | 青岛普瑞迈生物工程有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-110669801-B | Method for improving content of tremorine in secondary metabolite of Festuca sinensis-endophytic fungi strain PA | 兰州大学 | 2022-02-01 | — | — | CN | claimed |
| CN-111655856-A | Modular DNA assembly system | 维多利亚联结有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-110669801-A | Method for improving content of tremorine in secondary metabolite of Festuca sinensis-endophytic fungi strain PA | 兰州大学 | 2020-01-10 | — | — | CN | claimed |
| CN-106526167-A | Penitrem A combined antigen as well as preparation and application of antibody of antigen | 中国农业大学 | 2017-03-22 | — | — | CN | claimed |
| US-20140100198-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-04-10 | — | — | US | claimed |
| EP-2665739-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | claimed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | claimed |
| CN-101224207-A | Medicine for inducing autophagy and treating disease caused by wrong unfolded protein aggregation, and filtration method thereof | SHANGHAI INST ORGANIC CHEM (CN) | 2008-07-23 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673782-B1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORP (US) | 2000-06-14 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100198-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | LMNA 3983/4885CHRM1 4092/4885CHRM2 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.